{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-258156","form_type":"8-K","ticker":"INTI","cik":"0001042418","company_name":"Inhibitor Therapeutics, Inc.","filed_at":"2023-10-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.000817+00:00","generated_at":"2026-06-09T21:36:46.529239+00:00","sec_items":["5.02","5.03","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Inhibitor Therapeutics appoints Michelle Yanez as director, forms Scientific Advisory Board","bullets":["Michelle Yanez appointed as independent director and Audit Committee member, effective Oct 13, 2023.","Company creates SAB to advise on clinical development; Dr. Elizabeth Billingsley named chairperson.","Consulting agreement with Dermapharm Consulting LLC (Dr. Billingsley) at $600/hour for clinical trial support."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-258156","json":"https://secwatch.observer/filing/0001193125-23-258156.json","markdown":"https://secwatch.observer/filing/0001193125-23-258156.md","text":"https://secwatch.observer/filing/0001193125-23-258156.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1042418/000119312523258156/0001193125-23-258156-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1042418/000119312523258156/d562103d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T21:36:46.529239+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a72578d00a","claim":"Michelle Yanez was appointed as Director at Inhibitor Therapeutics, Inc..","evidence_excerpt":"On October 13, 2023, the Board of Directors (the “ Board ”) of Inhibitor Therapeutics, Inc. (the “ Company ”) appointed Michelle Yanez to fill one of the vacancies of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1042418/000119312523258156/0001193125-23-258156-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}